Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
Raanana, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage biotechnology company developing intranasal protective solutions, provided 2025 and recent a business update. "Polyrizon has delivered significant progress across its innovative nasal programs, including key regulatory advancements with the FDA, preparation for potential human clinical trials, and valuable medical collaborations, all powered by a strong cash position and a debt-free balance sheet," said Tomer Izraeli, chief executive officer of Polyrizon. Key Highlights of Polyrizon's Achievements in 2025 and Recent Highlights: As of December 31, 2025, t
Raanana, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2025, with the U.S. Securities and Exchange Commission (the "SEC"). The report is available on the SEC's website, at www.sec.gov and Polyrizon's Investor Relations website, at https://investor.polyrizon-biotech.com/. Shareholders can obtain copies of Polyrizon's Annual Report on Form 20-F, free of charge, by making a request within a reasonable period of time to Polyrizon's Investor Relat
The Company signed a non-binding MOU with shareholders of Colugo. Colugo's customer include the Israel Defense Forces, national first responders organizations and commercial companies Raanana, Israel, March 24, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced the signing of a non-binding Memorandum of Understanding ("MOU") with shareholders of Colugo Systems Ltd. ("Colugo"), an innovative Israeli developer of advanced electric Vertical Take-Off and Landing (eVTOL) drone systems, for the acquisition of up to 20% stake in Colugo. Established in 2016,
20-F/A - Polyrizon Ltd. (0001893645) (Filer)
20-F - Polyrizon Ltd. (0001893645) (Filer)
6-K - Polyrizon Ltd. (0001893645) (Filer)
3 - Polyrizon Ltd. (0001893645) (Issuer)
3 - Polyrizon Ltd. (0001893645) (Issuer)
3 - Polyrizon Ltd. (0001893645) (Issuer)
Raanana, Israel, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announce today the appointment of Dr. Michal Meir, Senior Consultant at MedTech SME Ltd., as Senior Director of Regulatory and Clinical Affairs. The appointment was made as part of the Company's preparations towards its clinical trial for PL-14 that is expected to commence in 2025. Dr. Meir brings over a decade of experience in the medical device and pharmaceutical industries, with a proven track record in regulatory strategy, clinical affairs management and product developmen
Raanana, Israel, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announces today the appointment of Asaf Azulay, the Managing Director of Eurofins' Li-Med team, to its leadership as its VP of Regulatory Affairs and Quality Assurance (RA/QA). This strategic appointment reflects Polyrizon's ongoing commitment to maintaining the highest industry standards as it advances its pipeline of cutting-edge solutions. Asaf Azulay brings over 20 years of extensive experience in the medical devices industry, with expertise in leading quality teams and i